Hjem › Wilms tumor › District of Columbia
Kliniske studier for Wilms tumor i District of Columbia
7 studier for Wilms tumor søker deltakere på steder i District of Columbia.
Byer i District of Columbia
Offisiell studietekst (engelsk)
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
- Children's National Medical Center, Washington D.C.
RekruttererFase 2
Alder 12 til 39 · Alle kjønn · Oppdatert 29. sep. 2026 · NCT04616560Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's National Medical Center, Washington D.C.
RekruttererFase 1/2
12 Months – 30 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04851119A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- MedStar Georgetown University Hospital, Washington D.C.
- Children's National Medical Center, Washington D.C.
RekruttererFase 2
Opp til 30 år · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04322318Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
- Children's National Hospital, Washington D.C.
- Childrens National Hospital, Washington D.C.
RekruttererFase 1
Alder 1 til 23 · Alle kjønn · Oppdatert 13. aug. 2026 · NCT07172958Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
- Children's National Medical Center, Washington D.C.
RekruttererFase 1/2
12 Months – 30 Years · Alle kjønn · Oppdatert 19. mai 2026 · NCT04901702A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
- Children's National Hospital (Data Collection Only), Washington D.C.
RekruttererFase 2
12 Months · Alle kjønn · Oppdatert 6. mai 2026 · NCT05985161A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
- Children's National Medical Center, Washington D.C.
RekruttererFase 2
18 Months – 40 Years · Alle kjønn · Oppdatert 12. aug. 2025 · NCT05135975Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.